Synopsys SNPS has outperformed the market over the past 20 years by 10.25% on an annualized basis producing an average annual ...

Synopsys (SNPS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth ...

Today we're going to take a look at the well-established Synopsys, Inc. ( NASDAQ:SNPS ). The company's stock received ...

Shares of Synopsys Inc. SNPS inched 0.21% higher to $506.83 Tuesday, on what proved to be an all-around positive trading ...

Synopsys Inc (SNPS) stock saw a modest uptick, ending the day at $514.12 which represents a slight increase of $18.17 or 3.66% from the prior close of $495.95. The stock opened at $517.18 and touched ...

Below is Validea's guru fundamental report for SYNOPSYS INC (SNPS). Of the 22 guru strategies we follow, SNPS rates highest using our P/B Growth Investor model based on the published strategy of ...

Shares of Synopsys Inc. SNPS shed 0.17% to $505.79 Monday, on what proved to be an all-around favorable trading session for ...

It has been about a month since the last earnings report for Synopsys (SNPS). Shares have lost about 6.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

While smoking rates are declining in other parts of the world, data shows that the African region and other Low-Income ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.